OVERVIEW
Our highly differentiated antimicrobial product pipeline utilizes our patented bisphosphocin™ class to target various indications suitable for topical treatment. The first indication moving into phase 2 I in patients with infected diabetic foot ulcers.
Bisphosphocins are novel small protonated nucleotide derivative molecules that exert their antibacterial activity by depolarization and rupture of the bacterial cell membranes, causing rapid bacterial cell death. Preclinical studies have demonstrated efficacy against more than 70 bacterial strains, including all the ESKAPE pathogens and clinically isolated bacterial strains such as Methicillin-resistant Staphylococcus aureus (MRSA) and Methicillin-sensitive Staphylococcus aureus (MSSA). Our bisphosphocin technology currently has 38 patents issued, with coverage extending to 2038.